NEW YORK (GenomeWeb News) – Kinaxo Biotechnologies said today that it will use its mass spectrometry platform to quantitatively analyze post-translational modifications of proteins for Boehringer Ingelheim.
 
Kinaxo, a spinout of the Max-Planck Institute of Biochemistry based in Martinsried, Germany, will use its Cellular Target Profiling technology to study the effects of different compounds on proteome-wide signal transduction pathways for the drugmaker.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.